p applicant Rising 
World of DTC Marketing
FEBRUARY 1, 2022
Over the past year, the iShares Biotechnology ETF IBB, +3.04% declined 23.3%, the Nasdaq Biotechnology Index NBI, +2.86% fell 20.4%, and the SPDR S&P Biotech ETF XBI, +5.48% tumbled 41.9%; the broader S&P 500 SPX, +1.89% , however, is up 13.0%. . All of this comes amid a backdrop of rising interest rates.
World of DTC Marketing
DECEMBER 15, 2020
SUMMARY: Deloitte predicts that the percentage of virtual video visits to doctors will rise to 5% globally in 2021, up from an estimated 1% in 2019. Historically, research has shown that elderly users, even when they have the right tools and connections, are still less likely to use digital applications, in part due to unfamiliarity.11
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
DECEMBER 12, 2023
This growth is primarily being driven by a rise in neurological diseases like stroke, dementia and peripheral neuropathy, coupled with increased R&D funding for neurological research. The reasons for their rising prominence are manifold. Importantly, FDA-approved products are now available for these PET imaging applications.
Roots Analysis
FEBRUARY 22, 2022
With the increasing global population, the incidence rates of several chronic disease indications, such as diabetes, anaphylaxis, rheumatoid arthritis and psoriasis, are on the rise. This has led to a rise in the demand for effective treatment options for patients suffering from these diseases. Our Social Media Platform. Web: [link].
ACRP blog
NOVEMBER 1, 2023
That was very exciting,” says Chauhan, who also has a BSc in engineering physics, which he calls a degree in “problem-solving.” The researchers tell ACRP that their tool is applicable to patient outcomes generated from virtually any kind of trial design.
ACRP blog
NOVEMBER 1, 2023
That was very exciting,” says Chauhan, who also has a BSc in engineering physics, which he calls a degree in “problem-solving.” The researchers tell ACRP that their tool is applicable to patient outcomes generated from virtually any kind of trial design.
Delveinsight
JANUARY 28, 2021
Nirogy Therapeutics rises with USD 16.5 Iterum Therapeutics presents new drug application to FDA for Oral Sulopenem. They were astonished to discover that the gut bacteria exhibited enhanced L-tyrosine metabolism, resulting in a byproduct known as p-cresol sulfate (PCS). Million to target metabolite transporters.
Expert insights. Personalized for you.
234 
Let's personalize your content